Table 1.
Personal characteristics of field test sample. Values are numbers (percentages) of participants unless stated otherwise
| Characteristics | Respondents (n=274) |
|---|---|
| Age (years): | |
| Mean (SD)*; range | 45.0 (10.0); 21-70 |
| Sex: | |
| Female | 240 (88) |
| Male | 34 (12) |
| Ethnicity: | |
| White | 253 (92) |
| Asian or Asian British | 7 (3) |
| Black, African, Caribbean, or black British | 3 (1) |
| Mixed or multiple ethnic groups | 11 (4) |
| Other ethnic group | 0 (0) |
| Occupational status: | |
| Employed full time | 114 (42) |
| Employed but currently not working | 51 (19) |
| Employed part time | 39 (14) |
| Furloughed | 7 (3) |
| Retired | 6 (2) |
| Caregiver | 3 (1) |
| In full time education | 3 (1) |
| Voluntary work | 3 (1) |
| Unemployed | 20 (7) |
| Other | 28 (10) |
| Month and year of SARS-Co-V-2 infection: | |
| December 2019 | 3 (1) |
| January-December 2020 | 233 (85) |
| January-May 2021 | 38 (14) |
| Positive PCR test result for SARS-Co-V-2 infection†: | |
| Yes | 129 (47) |
| No | 137 (50) |
| Do not know | 8 (3) |
| Positive lateral flow test result for SARS-Co-V-2 infection†: | |
| Yes | 22 (8) |
| No | 227 (83) |
| Do not know | 25 (9) |
| Admitted to hospital for SAR-Co-V-2 infection: | |
| Yes | 11 (4) |
| No | 263 (96) |
| Admitted to ICU for SARS-Co-V-2 infection: | |
| Yes | 0 (0) |
| No | 274 (100) |
| Attended hospital emergency department for SARS-Co-V-2 infection: | |
| Yes | 111 (41) |
| No | 163 (59) |
| Vaccine status: | |
| Two doses | 187 (68) |
| One dose | 70 (25) |
| No dose | 17 (6) |
| Received shielding letter from UK government‡: | |
| Yes | 12 (4) |
| No | 262 (96) |
| Care home resident: | |
| Yes | 3 (1) |
| No | 271 (99) |
| Mean (SD) EQ-5D-5L utility score | 0.490 (0.253) |
SD=standard deviation; PCR=polymerase chain reaction; ICU=intensive care unit; EQ-5D-5L=health related quality of life instrument.
n=263 respondents.
Owing to difficulties accessing PCR and lateral flow tests in the early weeks of the pandemic, not all participants had access to testing.
Letter to indicate clinical vulnerability requiring enhanced social distancing.